The Pharma Data

JUNE 7, 2023

3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. Rahway, NJ, USA), an anti-PD-1 therapy. 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. Rahway, NJ, USA), an anti-PD-1 therapy. The percentage of ILD or pneumonitis events was similar across cohorts.

Trials 40

Trials Protein Expression Therapies Treatment 40

The Pharma Data

APRIL 26, 2022

No vaccine-related serious adverse events (SAEs) were observed. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

JANUARY 13, 2021

Dr. Lederman continued, “Despite the recognized promise of anti-CD40-ligand mAb therapy, first generation anti-CD40-ligand mAbs were limited because their crystallizable fragment (Fc) domain interacted with a cell surface receptor called Fc?RII, RII, which resulted in an increased risk of thrombosis. International Immunol. (11):1583

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It It was by Nicholas Field, Principal Scientist, Purification Development, Lonza, titled: ‘Tailored CMC solutions to overcome the challenges in bispecific, Fab and Fc-fusion protein development programs’.

Protein Expression 148

Protein Expression Engineering DNA Therapies 148

The Pharma Data

OCTOBER 28, 2020

Preliminary results from the first five patients treated indicate substantial improvements in all patients in at least two disease domains including communication, behavior, sleep, gross motor function, and fine motor function as measured by the Clinical Global Impression of Improvement Scale for Angelman Syndrome (CGI-I-AS) at day 128.

Protein Expression 40

Protein Expression Production Therapies Treatment 40

The Pharma Data

APRIL 8, 2021

FDA and global approvals for our groundbreaking therapies in SMA and NMOSD, Roche’s data at AAN reflect our continued commitment to meaningful therapeutic progress for people living with neurological disorders,” said Levi Garraway, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We Following U.S.

Clinical Trials 52

Clinical Trials Trials Disease Nurses 52

The Pharma Data

AUGUST 9, 2021

The safety profile of Enhertu was consistent with previous clinical trials, with no new safety concerns identified and no Grade 4 or 5 treatment-related interstitial lung disease events. 1 More than two million patients with breast cancer were diagnosed in 2020, resulting in nearly 685,000 deaths globally.

Trials 52

Trials Treatment Clinical Trials Protein Expression 52